The high prevalence of genomic alterations that involve DDR genes in prostate cancer has been recognised over the past 5 years.8–14 In 2015, The Cancer Genome Atlas (TCGA) published the molecular analysis of 333 primary prostate tumours, revealing that 19% of them harboured alterations in different DDR genes, including BRCA2, BRCA1, ATM, CDK12, FANCD2 or RAD51C. 12 Even though BRCA2 was reported as the most commonly altered gene, all six cases with germline BRCA2 mutations presented with the same variant, p.K3326* (the pathogenic significance of which is unclear). Here, BRCA2 is linked to prostate carcinoma.